| scholarly article | Q13442814 |
| P2093 | author name string | Xinbin Chen | |
| Wensheng Yan | |||
| P2860 | cites work | The role of CDP in the negative regulation of CXCL1 gene expression | Q24647127 |
| Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II | Q24681272 | ||
| A system for stable expression of short interfering RNAs in mammalian cells | Q27860875 | ||
| Receptor recognition and specificity of interleukin-8 is determined by residues that cluster near a surface-accessible hydrophobic pocket | Q28278246 | ||
| p53: puzzle and paradigm | Q29618407 | ||
| Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins | Q34104923 | ||
| Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma | Q34354735 | ||
| Chemokines in tumor angiogenesis and metastasis | Q34540743 | ||
| Role of CXCL1 in tumorigenesis of melanoma. | Q34724089 | ||
| CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer | Q36228506 | ||
| Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling | Q36462813 | ||
| Transcription regulation by mutant p53. | Q36777349 | ||
| Growth related oncogene-alpha (GRO-alpha): roles in atherosclerosis, angiogenesis and other inflammatory conditions | Q36833950 | ||
| Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. | Q37149860 | ||
| An NF-kappa B-like transcription factor mediates IL-1/TNF-alpha induction of gro in human fibroblasts | Q38334326 | ||
| Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain | Q39575066 | ||
| Tumor-derived p53 mutants induce NF-kappaB2 gene expression | Q39614332 | ||
| Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. | Q39979160 | ||
| Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. | Q40052470 | ||
| Targeted repression of bone morphogenetic protein 7, a novel target of the p53 family, triggers proliferative defect in p53-deficient breast cancer cells | Q40073640 | ||
| Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. | Q40203796 | ||
| Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways | Q40291598 | ||
| Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis | Q40291696 | ||
| A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer | Q40304146 | ||
| HMGI(Y) and Sp1 in addition to NF-kappa B regulate transcription of the MGSA/GRO alpha gene | Q40396385 | ||
| Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism | Q40865256 | ||
| E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways | Q40908814 | ||
| Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity/GRO alpha gene requires both NF-kappa B and novel constitutive factors | Q41258049 | ||
| KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway | Q42818551 | ||
| p21B, a variant of p21(Waf1/Cip1), is induced by the p53 family | Q43890977 | ||
| Role of melanoma growth stimulatory activity (MGSA/gro) on keratinocyte function in wound healing | Q46309627 | ||
| Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression | Q46709821 | ||
| Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. | Q52561781 | ||
| The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells. | Q54652592 | ||
| Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. | Q54658705 | ||
| The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers | Q74523161 | ||
| Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells | Q79961179 | ||
| Analysis of protein-DNA binding by streptavidin-agarose pulldown | Q80058687 | ||
| Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix | Q81428298 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 12178-12187 | |
| P577 | publication date | 2009-03-03 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Identification of GRO1 as a critical determinant for mutant p53 gain of function | |
| P478 | volume | 284 |
| Q35501591 | ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers |
| Q30498194 | Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma |
| Q33597685 | Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells |
| Q28541801 | Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase |
| Q33825155 | Characterization of functional domains necessary for mutant p53 gain of function |
| Q37816561 | Chemokines in cancer related inflammation |
| Q37423073 | Differential regulation of the REGγ-proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells |
| Q89805344 | Gain-of-Function Mutations in p53 in Cancer Invasiveness and Metastasis |
| Q35078954 | High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H. |
| Q36019774 | Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. |
| Q92255972 | Increased prefrontal cortex interleukin-2 protein levels and shift in the peripheral T cell population in progressive supranuclear palsy patients |
| Q31048838 | Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap Trios, and relation to fragile site location |
| Q35914917 | Mutant p53 cooperates with ETS2 to promote etoposide resistance |
| Q34963520 | Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q64892305 | Mutant p53 in cancer therapy-the barrier or the path. |
| Q38197826 | Mutant p53 in cancer: new functions and therapeutic opportunities |
| Q30313610 | Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. |
| Q34978872 | Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression |
| Q41490261 | Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells |
| Q89944650 | Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells |
| Q33825046 | Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function |
| Q36070574 | Mutant p53: one name, many proteins |
| Q41585790 | NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity |
| Q38846785 | Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation |
| Q34938075 | Poly (C)-binding protein 1 regulates p63 expression through mRNA stability |
| Q28547113 | TGF-β Negatively Regulates CXCL1 Chemokine Expression in Mammary Fibroblasts through Enhancement of Smad2/3 and Suppression of HGF/c-Met Signaling Mechanisms |
| Q91643844 | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors |
| Q28546913 | The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes |
| Q37225303 | The consequence of oncomorphic TP53 mutations in ovarian cancer |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q39005896 | Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. |
| Q37582777 | When mutants gain new powers: news from the mutant p53 field. |
| Q38069463 | p53 mutations in cancer |
| Q89783061 | p53's Extended Reach: The Mutant p53 Secretome |
| Q39363650 | p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability |
Search more.